What “agentic AI” means in a validated environment
An AI agent takes a goal, decides on a sequence of steps, calls systems to carry them out, and returns a result. That is a different thing from a chat assistant that answers a question, and the difference is exactly what a validated environment cares about.
A chatbot produces text a human reads and acts on. The human is the control. An agent acts, and the record of why it acted becomes the control. Under ALCOA+ that record has to be attributable, legible, contemporaneous, original and accurate, and it has to be reproducible later by someone who was not there.
That is the requirement. It does not change because the software is new.
For the underlying capability definitions, see What Is an Agentic AI Platform? A Buyer’s Guide for 2026.
The thing no vendor can sell you
There is no GxP certification for a cloud service provider, and there is no FDA 21 CFR Part 11 certification either. Compliance is established by the regulated company through its own risk-based validation, informed by FDA’s Computer Software Assurance guidance, ISPE’s 2025 GAMP AI Guide, and ICH Q9(R1) on quality risk management.
Read any vendor’s compliance page with that in mind. A platform can give you the controls that make validation tractable: audit logging, access control, data residency, reproducibility, an intended-use statement you can validate against. It cannot give you the validation. That work stays with you, and the amount of it left over is the honest basis for comparing these platforms.
So the question in each section below is not “is this compliant.” It is: what does this platform do for you, and what does it leave on your desk?
What to evaluate
Six things, in the order they usually bite.
Context of use. What decisions is the agent making, and what happens if it is wrong. Risk classification drives everything downstream, and both the ISPE and FDA frameworks are built around it. A literature-summarising agent and a batch-record-review agent are not the same validation problem.
The decision record. Not whether there is logging, but whether a single decision can be reconstructed later: what the agent decided, on what evidence, under whose authority, and with the source documents attached.
Chain length. A supervisor agent routing across specialised sub-agents introduces a longer chain of decisions, each of which needs to be logged, attributable and reproducible. More autonomy is more surface area between the trigger and the human review.
Where the data sits. Data residency, tenancy, and whether your regulated content ever leaves a boundary you control.
Reach across systems. Most life sciences workflows cross a QMS, a LIMS, an ERP, a document vault and a handful of spreadsheets. A platform that only reaches inside its own suite solves the part of the workflow that was already easy.
What is left for you to validate. Ask every vendor to state it plainly. The good ones do.
The six
Not a ranking. Six different situations, and the right answer depends on which one you are in.
We publish this page and we are first on it. What that should mean in practice: every other platform gets a lane it genuinely owns, our own entry names what it is not for, and not one of the six is described as compliant, because not one of them can be.
1. Dataworkz — the cross-system agent estate
Best for: organisations running agents across many systems at once, where the hard requirement is reconstructing any single decision later.
Most life sciences workflows do not sit inside one vendor’s suite. A deviation investigation touches the QMS, the LIMS, the batch record and a shared drive. Dataworkz is built for the estate rather than for one application: agents reach across systems through more than 100 connectors, and every decision carries its reasoning and its source documents as a queryable, exportable record.
It sits alongside Vault, your QMS and your LIMS rather than replacing them. Your validated systems of record stay where they are, and the agent works across them.
Key features
- Per-decision audit logging with reasoning and source documents attached, timestamped and exportable
- Access control enforced at the level of the retrieved content chunk, not the folder
- Deterministic control over agent plans where a step must not vary between runs
- SOC 2 Type II and CASA Tier 2, with managed SaaS, dedicated SaaS or in-VPC deployment
- LLM-agnostic, so a model change is not a re-platforming
Pros: the decision record is designed in rather than assembled afterwards, which is the part of a validation package that is usually hardest to retrofit. Cross-system reach means the agent covers the whole workflow rather than the part that happened to live in one application.
Cons: the payoff is proportional to how much of the workflow crosses systems, so a task that lives entirely inside one application will not show the difference.
2. Microsoft 365 Copilot and Azure AI Foundry — the document surface
Best for: organisations whose regulated work happens inside Word, Excel, Outlook and Teams, and who want assistance where the documents already are.
Microsoft has the broadest existing footprint in pharma of anything on this list, which matters more than any feature comparison. Its GxP guidance for Azure has been reviewed with Montrium, and Azure AI Foundry gives you a place to build and host agents inside a tenancy you already own and have probably already assessed.
Key features
- Assistance embedded in the applications where regulated documents are authored
- Azure AI Foundry for building and hosting custom agents
- Published GxP guidance for the underlying platform
- Tenancy and identity you have already validated for other systems
Pros: lowest adoption friction of anything here. Existing security review is largely reusable. Cons: no native Part 11 certification, and validation responsibility sits with the deploying company. The centre of gravity is the document, so cross-system workflows need building elsewhere.
3. Google Gemini Enterprise — connected data and no-code agents
Best for: teams whose first constraint is data sovereignty and whose builders are not engineers.
Gemini Enterprise leads on cross-organisational data connectors and on letting non-developers assemble agents, with explicit VPC Service Controls and data sovereignty options on higher tiers.
Key features
- Broad connector coverage across organisational data sources
- No-code agent construction
- VPC Service Controls and data residency options
- Google Cloud compliance posture underneath
Pros: strong controls at the infrastructure layer, and a low barrier for non-engineers to build something real. Cons: the compliance story is infrastructure-level. It says what Google does with your data, not what your agent did with it, and the agent-level record is the part a Part 11 assessment asks about.
4. OpenAI ChatGPT Enterprise and ChatGPT for Healthcare — general assistance under a BAA
Best for: organisations that want broad workforce assistance with HIPAA coverage in place, where the use cases are not GxP-critical.
The healthcare ecosystem around OpenAI is the most mature of the frontier labs, and BAA availability at the Enterprise and API tiers settles a question that otherwise stalls procurement.
Key features
- BAA availability for Enterprise and API tiers
- Large and active healthcare implementation ecosystem
- General-purpose capability across a wide range of tasks
Pros: the fastest way to put capable assistance in front of a lot of people, with the HIPAA question answered. Cons: public GxP-specific guidance is thinner than the HIPAA-oriented material. For validated workflows you will be constructing the compliance argument yourself with less vendor documentation to lean on.
5. Anthropic Claude Enterprise and Claude for Life Sciences — connected to the research stack
Best for: scientific and research workflows where the value is in reaching lab and literature systems directly.
The distinguishing feature is what it connects to. Pre-built connectors into Benchling, PubMed and BioRender put the agent next to the systems research teams actually use, and inference geography can be pinned per request rather than only per tenant.
Key features
- Pre-built connectors to Benchling, PubMed and BioRender
- Per-request control of inference geography, currently US or global only
- Strong long-document handling for protocols, literature and submissions
Pros: the most life-sciences-aware connector set of the general platforms, which shortens the distance from pilot to something a scientist uses daily. Cons: no native GxP certification. The connectors serve research workflows better than manufacturing and quality ones, and first-party data residency offers only US or global inference with US-only storage at rest, which matters if you are working to EU Annex 11.
6. AWS Bedrock with Veeva Vault AI — the validated system of record
Best for: organisations already standardised on Veeva Vault, who want agents operating against a validated platform layer rather than beside one.
This is the closest thing on the list to GxP-native, because the system of record is already a validated platform in most life sciences estates. AWS Config conformance packs exist for Part 11 and EU Annex 11, which gives you a starting control set rather than a blank page.
Key features
- Agents operating against Vault as a validated system of record
- AWS Config conformance packs covering Part 11 and EU Annex 11
- Consumption-based model on Bedrock, agent capability bundled into Vault licensing
- Multi-agent construction on Bedrock
Pros: if Vault is already your document and quality backbone, this is the shortest path to agents that act on regulated content without moving it. Cons: meaningful integration overhead, and it presumes an existing Vault footprint or in-house engineering. Outside the Vault estate the advantage largely disappears.
Choosing between them
Three questions settle it in most cases.
Does the workflow cross systems? If not, use the agents built into the system it lives in. If it does, a suite-bound agent will only ever cover part of it.
What is the context of use? Literature summarisation and batch record review sit at opposite ends of the risk scale, and the validation effort should be proportionate. Do not build a Part 11 case around a tool nobody uses for regulated decisions.
How long is the chain? Every additional autonomous step is another decision to evidence. The shortest chain that does the job is usually the right architecture, and it is always the cheaper one to validate.